Promimic AB (publ) (PRO.ST)
SEK 25.8
(-1.15%)
SEK 25.8
(-1.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 16.15 Million SEK | 41.03% |
| 2022 | 11.45 Million SEK | 19.4% |
| 2021 | 9.59 Million SEK | 31.93% |
| 2020 | 7.27 Million SEK | 9.83% |
| 2019 | 6.62 Million SEK | -8.43% |
| 2018 | 7.23 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 11.06 Million SEK | -18.86% |
| 2024 Q1 | 13.64 Million SEK | -15.57% |
| 2023 Q2 | 10.82 Million SEK | 9.85% |
| 2023 FY | 16.15 Million SEK | 41.03% |
| 2023 Q4 | 16.15 Million SEK | 67.07% |
| 2023 Q3 | 9.67 Million SEK | -10.66% |
| 2023 Q1 | 9.85 Million SEK | -13.99% |
| 2022 Q2 | 11.11 Million SEK | -4.87% |
| 2022 Q4 | 11.45 Million SEK | 100.21% |
| 2022 Q3 | 5.72 Million SEK | -48.5% |
| 2022 FY | 11.45 Million SEK | 19.4% |
| 2022 Q1 | 11.67 Million SEK | 21.72% |
| 2021 Q4 | 9.59 Million SEK | 63.63% |
| 2021 Q3 | 5.86 Million SEK | -14.61% |
| 2021 FY | 9.59 Million SEK | 31.93% |
| 2021 Q2 | 6.86 Million SEK | -5.13% |
| 2021 Q1 | 7.23 Million SEK | 0.0% |
| 2020 FY | 7.27 Million SEK | 9.83% |
| 2019 FY | 6.62 Million SEK | -8.43% |
| 2018 FY | 7.23 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -46.899% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.396% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 99.396% |
| Arcoma AB | 33.3 Million SEK | 51.491% |
| Bactiguard Holding AB (publ) | 329.7 Million SEK | 95.1% |
| BICO Group AB (publ) | 3.26 Billion SEK | 99.505% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | 94.228% |
| CellaVision AB (publ) | 212.32 Million SEK | 92.391% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -13.799% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -135.204% |
| C-Rad AB (publ) | 122.4 Million SEK | 86.801% |
| Duearity AB (publ) | 17.53 Million SEK | 7.838% |
| Dignitana AB (publ) | 37.56 Million SEK | 56.994% |
| Episurf Medical AB (publ) | 19.8 Million SEK | 18.404% |
| Getinge AB (publ) | 24.69 Billion SEK | 99.935% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | 21.574% |
| Iconovo AB (publ) | 14.55 Million SEK | -11.008% |
| Integrum AB (publ) | 22.07 Million SEK | 26.806% |
| Luxbright AB (publ) | 7 Million SEK | -130.796% |
| Mentice AB (publ) | 163.55 Million SEK | 90.122% |
| OssDsign AB (publ) | 105.25 Million SEK | 84.651% |
| Paxman AB (publ) | 44.5 Million SEK | 63.702% |
| Qlife Holding AB (publ) | 62.16 Million SEK | 74.013% |
| SciBase Holding AB (publ) | 21.27 Million SEK | 24.072% |
| ScandiDos AB (publ) | 37.18 Million SEK | 56.554% |
| Sectra AB (publ) | 1.64 Billion SEK | 99.016% |
| Sedana Medical AB (publ) | 44.06 Million SEK | 63.333% |
| Senzime AB (publ) | 58.06 Million SEK | 72.176% |
| SpectraCure AB (publ) | 14.97 Million SEK | -7.886% |
| Stille AB | 172.64 Million SEK | 90.642% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 99.56% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | 93.552% |